Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment of naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open label, phase 2 trial

被引：0
|
作者：
不详
机构：
来源：
CHIMICA OGGI-CHEMISTRY TODAY | 2018年 / 36卷 / 02期
关键词：
Oligonucleotide; phosphorothioate; polymeric nanoparticles; nucleic acid polymer (NAP); hepatitis D co-infection; hepatitis B virus surface antigen (HBsAg); pegylated interferon alfa-2a; antiviral activity;
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
引用
收藏
页码：54 / 55
页数：2
相关论文
共 50 条
  • [1] Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial
    Bazinet, Michel
    Pantea, Victor
    Cebotarescu, Valentin
    Cojuhari, Lilia
    Jimbei, Pavlina
    Albrecht, Jeffrey
    Schmid, Peter
    Le Gal, Frederic
    Gordien, Emmanuel
    Krawczyk, Adalbert
    Mijocevic, Hrvoje
    Karimzadeh, Hadi
    Roggendorf, Michael
    Vaillant, Andrew
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2017, 2 (12): : 877 - 889
  • [2] Safety and efficacy of REP 2139 and pegylated interferon alfa-2α for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial (vol 2, pg 877, 2017)
    Bazinet, M.
    Pantea, V
    Cebotarescu, V
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2018, 3 (01): : E1 - E1
  • [3] Initial Follow Up Results from the REP 301 Trial: Safety and Efficacy of REP 2139-Ca and Pegylated Interferon Alpha-2a in Caucasian Patients with Chronic HBV / HDV Co-infection
    Bazinet, Michel
    Pantea, Victor
    Cebotarescu, Valentin
    Cojuhari, Lilia
    Jimbei, Paulina
    Albrecht, Jeffrey
    Schmid, Peter
    Krawczyk, Adalbert
    Karimzadeh, Hadi
    Roggendorf, Michael
    Valliant, Andrew
    HEPATOLOGY, 2016, 64 : 912A - 912A
  • [4] Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients With Chronic HBV Infection Naive to Nucleos(t)ide Therapy
    Bazinet, Michel
    Pantea, Victor
    Placinta, Gheorghe
    Moscalu, Iurie
    Cebotarescu, Valentin
    Cojuhari, Lilia
    Jimbei, Pavlina
    Iarovoi, Liviu
    Smesnoi, Valentina
    Musteata, Tatiana
    Jucov, Alina
    Dittmer, Ulf
    Krawczyk, Adalbert
    Vaillant, Andrew
    GASTROENTEROLOGY, 2020, 158 (08) : 2180 - 2194
  • [5] Updated follow-up analysis in the REP 401 protocol: Treatment HBeAg negative chronic hepatitis B infection with REP 2139 or REP 2165, tenofovir disoproxil fumarate and pegylated interferon alfa-2a
    Vaillant, A.
    Bazinet, M.
    Pantea, V.
    Placinta, G.
    Moscalu, I.
    Cebotarescu, V.
    Cojuhari, L.
    Jimbei, P.
    Iarovoi, L.
    Smesnoi, V.
    Musteata, T.
    Jucov, A.
    Krawczyk, A.
    JOURNAL OF HEPATOLOGY, 2018, 68 : S517 - S517
  • [6] Establishment of persistent functional remission of HBV and HDV infection following REP 2139 and pegylated interferon alpha 2a therapy in patients with chronic HBV/HDV co-infection: 18 month follow-up results from the REP 301-LTF study
    Bazinet, M.
    Pantea, V.
    Cebotarescu, V.
    Cojuhari, L.
    Jimbei, P.
    Vaillant, A.
    JOURNAL OF HEPATOLOGY, 2018, 68 : S509 - S509
  • [7] One year follow-up and HBV RNA / HBcrAg analysis in the REP 301 Trial: REP 2139 and pegylated interferon alpha-2a in Caucasian patients with chronic HBV / HDV co-infection
    Bazinet, M.
    Pantea, V.
    Cebotarescu, V.
    Cojuhari, L.
    Jimbei, P.
    Krawczyk, A.
    Vaillant, A.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S96 - S97
  • [8] ONGOING ANALYSIS OF FUNCTIONAL CONTROL / CURE OF HBV AND HDV INFECTION FOLLOWING REP 2139-CA AND PEGYLATED INTERFERON ALPHA-2a THERAPY IN PATIENTS WITH CHRONIC HBV / HDV CO-INFECTION: 3-YEAR FOLLOW-UP RESULTS FROM THE REP 301-LTF STUDY
    Bazinet, Michel
    Pantea, Victor
    Cebotarescu, Valentin
    Cojuhari, Lilia
    Jimbei, Pavlina
    Krawczyk, Adalbert
    Dittmer, Ulf
    Vaillant, Andrew
    HEPATOLOGY, 2019, 70 : 440A - 440A
  • [9] UPDATE ON THE SAFETY AND EFFICACY OF REP 2139 MONOTHERAPY AND SUBSEQUENT COMBINATION THERAPY WITH PEGYLATED INTERFERON ALPHA-2A IN CAUCASIAN PATIENTS WITH CHRONIC HBV/HDV CO-INFECTION
    Bazinet, M.
    Pantea, V.
    Cebotarescu, V.
    Cojuhari, L.
    Jimbei, P.
    Albrecht, J.
    Schmid, P.
    Krawczyk, A.
    Karimzadeh, H.
    Roggendorf, M.
    Vaillant, A.
    JOURNAL OF HEPATOLOGY, 2016, 64 : S584 - S585
  • [10] Update on the safety and efficacy of REP 2139 monotherapy and subsequent combination therapy with pegylated interferon alpha-2a in chronic HBV/HDV co-infection in Caucasian patients
    Bazinet, Michel
    Pantea, Victor
    Cebotarescu, Valentin
    Cojuhari, Lilia
    Jimbei, Paulina
    Albrecht, Jeffrey
    Schmid, Peter
    Karimzadeh, Hadi
    Roggendorf, Michael
    Vaillant, Andrew
    HEPATOLOGY, 2015, 62 : 222A - 222A
12345